Sanguine Corp. (SGUI) news stock charts
Sanguine Corp. (SGUI/SGUI.OB) Investment Summary:
Sanguine Corporation, a development stage company, engages in developing oxygen carriers used by the medical profession. It is developing a synthetic red blood cell product, PHER-O2 that consists of perfluoro-decalin molecules or synthetic red blood cells, purified water, and a synthetic and fluorinated surfactant to hold the emulsion together. PHER-O2 is under Phase II clinical trials and has oxygen-carrying capacity. Its various medical applications would include transportation of pancreas islets for treatment of diabetes, ophthalmic retinal surgery, and angioplasty; and external oxygenation of infection, ischemic tissue, and diabetic ulcers. PHER-O2 would also be used for Alzheimer’s, oxy...www.sanguine-corp.com
2 Employees
Founded in 1974
SANGUINE CORP (SGUI:OTC Bulletin Board Market)
LAST $0.17 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of 8:10 PM 03/18/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of SANGUINE CORP (SGUI)
|
OPEN
$0.17
|
PREVIOUS CLOSE
$0.17
|
|
|
DAY HIGH
$0.17
|
DAY LOW
$0.17
|
|
|
52 WEEK HIGH
05/20/09 - $0.51
|
52 WEEK LOW
07/6/09 - $0.10
|
|
|
MARKET CAP
1.1M
|
AVERAGE VOLUME 10 D
1.1K
|
|
|
EPS TTM
$-0.07
|
SHARES OUTSTANDING
6.7M
|
|
|
SGUI Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for SANGUINE CORP (SGUI)
Sanguine Corp. announced delayed 10-Q filing
11/12/2009
On 11/12/2009, Sanguine Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Sanguine Corp. will Change its Ticker to SGUI from SGUI.E
08/24/2009
Effective August 25, 2009, Sanguine Corp. will change its OTCBB stock ticker symbol to SGUI from SGUI.E.
Sanguine Corp. will Change its Ticker to SGUI from SGUIE
08/24/2009
Effective August 25, 2009, Sanguine Corp. will change its OTCBB stock ticker symbol to SGUI from SGUIE.
Sanguine Corp. financial resources
SGUI Competitors
| Company | Last | Change |
| Alliance Pharmaceutical Corp | $0.01 USD | 0.00 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | SGUI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
SGUI |
||
|
SGUI transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Sanguine Corp.
Sanguine Subsidiary to Change Name From Sanguine Life Sciences to SGN Life Sciences
2010-01-28 01:07:16
Quote: SGUINews) announced today
that it will change the name of its wholly-owned subsidiary, Sanguine Life
Sciences, to SGN Life Sciences.The Company explained that the name change
is necessary to better reflect the subsidiary's intended business model.
Company spokesperson, Mr. Frank Marra, explained, "When we decided to set
up the Sanguine Life Sciences subsidiary we did so primarily for the
purpose of seeking partnering relationships or merger candidates for
PHER-O2.However, it has become clear tha...Read article
Sanguine Corp Announces Letter of Commitment to License PHER-O2 to Rockland Technimed
2009-11-30 05:35:54
Quote: The ability to follow cellular respiration
in real-time
using an unaltered MRI in these patients is a paradigm shift
in the
management of these patients.Rockland Technimed's focus in MRI imaging is providing applications
in
tumor detection, tracking tumor angiogenesis, assess tissue
viability in
cases of Neurological and Cardiovascular catastrophes such
as Heart or
Stroke attack, or other tissue injury, and noninvasive real-time
tissue
stress monitoring to evaluate normal and abnormal oxygen
con...Read article
SANGUINE CORP Files SEC form 10-Q, Quarterly Report
2009-11-30 05:35:54
Quote: Drees has more than 33 years' experience in
the blood industry with Abbott Scientific, Alpha Therapeutics and Sanguine
Corporation.At this time we have not been able to obtain the necessary funding
to complete the above stages.Until we have the necessary funding, we will not
be able to complete the stages.
During the quarter ended September 30, 2008, the Company completed a 20 to 1
reverse stock split.Management believed the reverse was necessary to help
facilitate future financings.
Results of...Read article
SANGUINE CORP Files SEC form 10-Q, Quarterly Report
2009-11-30 05:35:53
Quote: Drees has more than 33 years' experience in
the blood industry with Abbott Scientific, Alpha Therapeutics and Sanguine
Corporation.At this time we have not been able to obtain the necessary funding
to complete the above stages.Until we have the necessary funding, we will not
be able to complete the stages.Additionally, the Company will be focusing on
other potential ventures that could produce revenue including licensing of its
PHER-02 product.
Results of Operations
The Company continues to no...Read article
SANGUINE CORP Files SEC form 10-K, Annual Report
2009-11-30 05:35:53
Quote: Drees has more than 33 years' experience in
the blood industry with Abbott Scientific, Alpha Therapeutics and Sanguine
Corporation.
Critical Accounting Policies and Estimates
The preparation of financial statements and related disclosures in conformity
with accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the amounts
reported in the unaudited Financial Statements and accompanying notes.
Management bases i...Read article
SANGUINE CORP Files SEC form 10-Q, Quarterly Report
2009-11-30 05:35:52
Quote: Drees has more than 33 years' experience in
the blood industry with Abbott Scientific, Alpha Therapeutics and Sanguine
Corporation.At this time we have not been able to obtain the necessary funding
to complete the above stages.Until we have the necessary funding, we will not
be able to complete the stages.Additionally, the Company will be focusing on
other potential ventures that could produce revenue including licensing of its
PHER-02 product.
Patents
Presently, we do not have any patents on ...Read article
Sanguine Subsidiary to Change Name From Sanguine Life Sciences to SGN Life Sciences
2009-11-30 05:35:52
Quote: SGUINews) announced today
that it will change the name of its wholly-owned subsidiary, Sanguine Life
Sciences, to SGN Life Sciences.The Company explained that the name change
is necessary to better reflect the subsidiary's intended business model.
Company spokesperson, Mr. Frank Marra, explained, "When we decided to set
up the Sanguine Life Sciences subsidiary we did so primarily for the
purpose of seeking partnering relationships or merger candidates for
PHER-O2.However, it has become clear tha...Read article
SANGUINE CORP Files SEC form 10-Q, Quarterly Report
2009-11-30 05:35:52
Quote: Drees has more than 33 years' experience in
the blood industry with Abbott Scientific, Alpha Therapeutics and Sanguine
Corporation.At this time we have not been able to obtain the necessary funding
to complete the above stages.Until we have the necessary funding, we will not
be able to complete the stages.Additionally, the Company will be focusing on
other potential ventures that could produce revenue including licensing of its
PHER-02 product.
Results of Operations
The Company continues to no...Read article
Would you like to leave a comment about Sanguine Corp. SGUI/SGUI.OB
Find out what social network information about Sanguine Corp. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Sanguine Corp.'s Stock there is more great penny stock and market information at Realpennies